Welcome to our dedicated page for Tg Therapeutics news (Ticker: TGTX), a resource for investors and traders seeking the latest updates and insights on Tg Therapeutics stock.
TG Therapeutics Inc (NASDAQ: TGTX) is a biopharmaceutical innovator advancing therapies for B-cell malignancies and autoimmune disorders. This dedicated news hub provides investors and industry professionals with essential updates on clinical developments, regulatory milestones, and corporate strategies.
Access real-time announcements including trial results, FDA submissions, and partnership agreements. Our curated collection ensures you never miss critical updates about ublituximab (BRIUMVI), PI3K delta inhibitors, or emerging pipeline candidates.
Key content categories include quarterly earnings reports, scientific conference presentations, manufacturing updates. All materials are sourced directly from company filings and verified industry publications.
Bookmark this page for streamlined tracking of TGTX's progress in developing glycoengineered antibody therapies and maintaining compliance with financial disclosure requirements. Check regularly for authoritative updates on this NASDAQ-listed biotech pioneer.
Precision BioSciences, Inc. (Nasdaq: DTIL) reported their first quarter 2024 financial results and provided a business update. The company is focused on advancing its wholly owned gene editing programs for Hepatitis B virus and primary mitochondrial myopathy. Precision also exercised the option to return three preclinical programs for internal development or with partners. They monetized CAR T assets through licensing deals and completed a $40 million common stock offering to extend cash runway into H2 2026. Financially, Precision had $137.8 million in cash and cash equivalents as of March 31, 2024, with total revenues of $17.6 million for the quarter. Research and development expenses increased to $13.3 million, while general and administrative expenses decreased to $8.4 million. Net income from continuing operations was $8.6 million for the quarter.
TG Therapeutics reported strong financial results for the first quarter of 2024 with BRIUMVI U.S. net revenue of $50.5 million, total revenue of $63.5 million, and updated yearly guidance to $270 to $290 million in BRIUMVI U.S. net revenue in 2024. The company is also making progress in clinical goals and advancing its pipeline. Recent highlights include the commercialization of BRIUMVI in the U.S. and Europe, obtaining additional patents, and entering into a global license agreement. Financially, the company saw significant growth in product revenue and net loss reduction.
TG Therapeutics, Inc. (NASDAQ: TGTX) will host a conference call on May 1, 2024, to discuss the first quarter financial results and the business outlook for 2024. The call will be led by Michael S. Weiss, Chairman and CEO. Participants can join via phone or webcast.
FAQ
What is the current stock price of Tg Therapeutics (TGTX)?
What is the market cap of Tg Therapeutics (TGTX)?
